Gut Restricted Therapeutic Approaches to Inflammatory Bowel Disease

Gut Restricted Therapeutic Approaches to Inflammatory Bowel Disease

pranab_maiti

Contact

Pranab Maiti

Contact

Rajiv Sharma

Contact

Gut Restricted Therapeutic Approaches to Inflammatory Bowel Disease

Article Fingerprint

ReserarchID

PDDTM3V175

Gut Restricted Therapeutic Approaches to Inflammatory Bowel Disease Banner

AI TAKEAWAY

Connecting with the Eternal Ground

Abstract

Inflammatory Bowel Disease (IBD), consisting of Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a chronic intestinal disorder that arises due to the damaged intestinal epithelium tissue, which most often leads to relapsing. Major treatment options range from dietary intervention at an early stage of the disease, to the use of steroids or anti-inflammatory drugs for most severe conditions. However, the side effects and associated comorbidities which bring disease recurrences points towards the unmet needs of the existing treatment options, which are limited to their non-holistic mechanistic functionality. Among them, many drugs work specifically by acting locally on the gut tissue, in other words at the site of the disease, both to exert maximal efficacy as well as to avoid undesired side effects. Here we have reviewed the recent interests in the gut restricted therapeutic approaches for new IBD therapies.

References

35 Cites in Article

Reference Format

Gilaad Kaplan (2015). The global burden of IBD: from 2015 to 2025.
Edward Loftus (2004). Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences.
B Hendrickson,R Gokhale,J Cho (2002). Clinical aspects and pathophysiology of inflammatory bowel syndrome.
Lauren Thurgate,Daniel Lemberg,Andrew Day,Steven Leach (2019). An Overview of Inflammatory Bowel Disease Unclassified in Children.
L Ray,Peterson Da,J Gordon (2006). Ecological and evolutionary forces shaping microbial diversity in the human intestine.
David Artis (2008). Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut.
A Ekbom,C Helmick,M Zack (1990). Ulcerative colitis and colorectal cancer: a population-based study New.
F Markus (2014). Cytokines in inflammatory bowel disease.
Marjolijn Duijvestein,Robert Battat,Niels Vande Casteele,Geert D’haens,William Sandborn,Reena Khanna,Vipul Jairath,Brian Feagan (2018). Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease.
P Schreiner,M Neurath,S Ng (2019). Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More.
Marc Fakhoury,Hani Al-Salami,Rebecca Negrulj,Armin Mooranian (2014). Inflammatory bowel disease: clinical aspects and treatments.
William Sandborn,Marc Ferrante,Bal Bhandari,Geert D'haens,Elina Berliba,Brian Feagan,Janelle Laskowski,Stuart Friedrich,Michael Durante,Jay Tuttle (2018). 882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study.
Alexander Moschen,Herbert Tilg,Tim Raine (2019). IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
C Xiaoli,T Lee,G Ledet (2017). The Biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, correlates with efficacy in a preclinical model of IBD.
A Bhandari,C Xiaoli,G Bourne (2016). Discovery of novel oral peptide antagonists of IL-23 receptor that are efficacious in rat model of IBD.
Pinyi Lu,Raquel Hontecillas,William Horne,Adria Carbo,Monica Viladomiu,Mireia Pedragosa,David Bevan,Stephanie Lewis,Josep Bassaganya-Riera (2012). Computational Modeling-Based Discovery of Novel Classes of Anti-Inflammatory Drugs That Target Lanthionine Synthetase C-Like Protein 2.
Philippe Bissel,Katie Boes,Jonathan Hinckley,Bernard Jortner,Geraldine Magnin-Bissel,Stephen Werre,Marion Ehrich,Adria Carbo,Casandra Philipson,Raquel Hontecillas,Noah Philipson,Richard Gandour,Josep Bassaganya-Riera (2016). Exploratory Studies With BT-11.
Andrew Leber,Raquel Hontecillas,Victoria Zoccoli-Rodriguez,Josep Bassaganya-Riera (2018). Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.
Andrew Leber,Raquel Hontecillas,Victoria Zoccoli-Rodriguez,Jean-Frederic Colombel,Jyoti Chauhan,Marion Ehrich,Nicholas Farinola,Josep Bassaganya-Riera (2020). The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.
Michael Murphy,Yanbao Xiong,Goutham Pattabiraman,Fu Qiu,Andrei Medvedev (2015). Pellino-1 Positively Regulates Toll-like Receptor (TLR) 2 and TLR4 Signaling and Is Suppressed upon Induction of Endotoxin Tolerance.
Gwanghee Lee,Younsook Lee,Mikyoung Chang,Sang Kang,Jeong-Hyun Ryou,Jong-Jin Lim,Ali Imran,Seok-Hee Park,Kwangho Lee,Yong-Hee Lee (2019). P120 BBT-401 IS A SELECTIVE PELLINO-1 PROTEIN-PROTEIN INTERACTION INHIBITOR IN CLINICAL DEVELOPMENT TARGETING A FIRST-IN-CLASS DRUG FOR UC TREATMENT..
(2019). Scenes from chemical congress in Las Vegas.
Carolina Palmela,Caroline Chevarin,Zhilu Xu,Joana Torres,Gwladys Sevrin,Robert Hirten,Nicolas Barnich,Siew Ng,Jean-Frederic Colombel (2018). Adherent-invasive <i>Escherichia coli</i> in inflammatory bowel disease.
Makrina Totsika,Maria Kostakioti,Thomas Hannan,Mathew Upton,Scott Beatson,James Janetka,Scott Hultgren,Mark Schembri (2013). A FimH Inhibitor Prevents Acute Bladder Infection and Treats Chronic Cystitis Caused by Multidrug-Resistant Uropathogenic Escherichia coli ST131.
Laurel Mydock-Mcgrane,Thomas Hannan,James Janetka (2017). Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s disease.
D Alvarez,A Sivignon,T Chalopini (2016). The Antiadhesive strategy in Crohn′s Disease: orally active mannosides to decolonize pathogenic escherichia coli from the gut.
Kailash Bhol,Daniel Tracey,Brenda Lemos,Gregory Lyng,Emma Erlich,David Keane,Michael Quesenberry,Amy Holdorf,Lisa Schlehuber,Shawn Clark,Barbara Fox (2013). AVX-470.
M Harris,D Hartman,B Lemos (2016). AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment for acute ulcerative colitis: results of a first-in-human trial.
J Bowser,L Phan,H Eltzschig (2018). The hypoxiaadenosine link during intestinal inflammation.
E Marks,C Naudin,G Nolan,B Goggins,G Burns,S Mateer,J Latimore,K Minahan,M Plank,P Foster,R Callister,M Veysey,M Walker,N Talley,G Radford-Smith,S Keely (2017). Regulation of IL-12p40 by HIF controls Th1/Th17 responses to prevent mucosal inflammation.
S Keely,E Campbell,A Baird,P Hansbro,R Shalwitz,A Kotsakis,E Mcnamee,H Eltzschig,D Kominsky,S Colgan (2014). Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.
Ellen Marks,Bridie Goggins,Jocelle Cardona,Siobhan Cole,Kyra Minahan,Sean Mateer,Marjorie Walker,Robert Shalwitz,Simon Keely (2015). Oral Delivery of Prolyl Hydroxylase Inhibitor.
Andrew King,Matthew Siegel,Ying He,Baoming Nie,Ji Wang,Samantha Koo-Mccoy,Natali Minassian,Qumber Jafri,Deng Pan,Jill Kohler,Padmapriya Kumaraswamy,Kenji Kozuka,Jason Lewis,Dean Dragoli,David Rosenbaum,Debbie O’neill,Allein Plain,Peter Greasley,Ann-Cathrine Jönsson-Rylander,Daniel Karlsson,Margareta Behrendt,Maria Strömstedt,Tina Ryden-Bergsten,Thomas Knöpfel,Eva Pastor Arroyo,Nati Hernando,Joanne Marks,Mark Donowitz,Carsten Wagner,R Alexander,Jeremy Caldwell (2018). Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
W Chey,A Lembo,D Rosenbaum (2020). Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
Jean Colombel,Jesse Hall,Monica Rosa,Bernard Mcdonald (2019). Tu1744 – Targeted Release Oral Cyclosporine (ST-0529) As a Potential New Therapy for Ulcerative Colitis: Phase I Study Results.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

pranab_maiti. 2021. \u201cGut Restricted Therapeutic Approaches to Inflammatory Bowel Disease\u201d. Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 21 (GJMR Volume 21 Issue B1).

More Citation Formats

Select Citation Style:

Download Citation

GJMR Volume 21 Issue B1

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-B Classification NLMC Code: QV 744

Submission ReceivedJune 14, 2021
Peer Review Double Blind
Handling Editor
Accepted July 1, 2021
Published July 15, 2021

Version of record

v1.2

Issue date

March 22, 2021

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Views: 2173

Total Downloads: 978

2026 Trends

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]